Abstract |
Aldosterone is a key signaling component of the renin-angiotensin-aldosterone system and as such has been shown to contribute to cardiovascular pathology such as hypertension and heart failure. Aldosterone synthase ( CYP11B2) is responsible for the final three steps of aldosterone synthesis and thus is a viable therapeutic target. A series of imidazole derived inhibitors, including clinical candidate 7n, have been identified through design and structure-activity relationship studies both in vitro and in vivo. Compound 7n was also found to be a potent inhibitor of 11β-hydroxylase ( CYP11B1), which is responsible for cortisol production. Inhibition of CYP11B1 is being evaluated in the clinic for potential treatment of hypercortisol diseases such as Cushing's syndrome.
|
Authors | Erik L Meredith, Gary Ksander, Lauren G Monovich, Julien P N Papillon, Qian Liu, Karl Miranda, Patrick Morris, Chang Rao, Robin Burgis, Michael Capparelli, Qi-Ying Hu, Alok Singh, Dean F Rigel, Arco Y Jeng, Michael Beil, Fumin Fu, Chii-Whei Hu, Daniel LaSala |
Journal | ACS medicinal chemistry letters
(ACS Med Chem Lett)
Vol. 4
Issue 12
Pg. 1203-7
(Dec 12 2013)
ISSN: 1948-5875 [Print] United States |
PMID | 24900631
(Publication Type: Journal Article)
|